Next Article in Journal
Sarcoidosis in Coexistence with Chronic Granulomatous Disease
Previous Article in Journal
Clinical Improvement in Job Syndrome Following Administration of Co-trimoxazole, Omalizumab and Inhaled Tobramycin
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 89
Issue 6
10.5603/ARM.a2021.0113
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Early Experience of Nintedanib in COVID-19 ARDS-Related Pulmonary Fibrosis: A Case Series

by
Marwah Vikas
1,2,
Robin Choudhary
1,2,*,
Virender Malik
1,2,
Arpita Pemmaraju
1,2 and
Deepu Peter
1,2
1
Army Institute of Cardiothoracic Science, Armed Forces Medical College, 411040 Pune, India
2
Army Institute of Cardiothoracic Sciences, Department of Pulmonary, Critical Care and Sleep Medicine, 411040 Pune, India
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2021, 89(6), 589-596; https://doi.org/10.5603/ARM.a2021.0113
Submission received: 30 March 2021 / Revised: 14 August 2021 / Accepted: 14 August 2021 / Published: 29 December 2021

Abstract

The current COVID-19 pandemic has spread like wildfire worldwide and has affected millions of people. The novel corona virus mainly affects the lungs leading to life threatening disease like acute respiratory distress syndrome (ARDS). The aftermath of the disease in form of pulmonary fibrosis is upcoming cause of further increase in morbidity and mortality. Nintedanib is an oral antifibrotics with proven role in idiopathic pulmonary fibrosis, however its use in COVID-19 related pulmonary fibrosis has not been studied. We report our early experience of use of nintedanib in COVID-19 related pulmonary fibrosis.
Keywords: SARS-CoV-2; ARDS; pulmonary fibrosis; antifibrotics; nintedanib SARS-CoV-2; ARDS; pulmonary fibrosis; antifibrotics; nintedanib

Share and Cite

MDPI and ACS Style

Vikas, M.; Choudhary, R.; Malik, V.; Pemmaraju, A.; Peter, D. Early Experience of Nintedanib in COVID-19 ARDS-Related Pulmonary Fibrosis: A Case Series. Adv. Respir. Med. 2021, 89, 589-596. https://doi.org/10.5603/ARM.a2021.0113

AMA Style

Vikas M, Choudhary R, Malik V, Pemmaraju A, Peter D. Early Experience of Nintedanib in COVID-19 ARDS-Related Pulmonary Fibrosis: A Case Series. Advances in Respiratory Medicine. 2021; 89(6):589-596. https://doi.org/10.5603/ARM.a2021.0113

Chicago/Turabian Style

Vikas, Marwah, Robin Choudhary, Virender Malik, Arpita Pemmaraju, and Deepu Peter. 2021. "Early Experience of Nintedanib in COVID-19 ARDS-Related Pulmonary Fibrosis: A Case Series" Advances in Respiratory Medicine 89, no. 6: 589-596. https://doi.org/10.5603/ARM.a2021.0113

Article Metrics

Back to TopTop